B cells have been shown to be effective for predicting which cancer patients will respond to immune checkpoint blockade therapy, according to a study at MD Anderson Cancer Center. Study results will be presented April 2 at the AACR Annual Meeting 2019 in Atlanta.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
